Broadly Applicable Nanowafer Drug Delivery System for Treating Eye Injuries
Abstract
Eye injuries require immediate and effective treatment to prevent corneal opacification, neovascularization , irregularity and occasionally ulceration of the cornea, which can be potentially blinding. Eye injuries are generally treated with eye drops for 4-8 times per day, which may not be feasible in critically injured patients in intensive care. This research project aims to develop a nanowafer drug delivery system that can deliver the drug to the eye for longer periods of time to treat eye injuries and prevent potential loss of vision. During the second year of this project, the nanowafer fabrication and drug release in the eye have been optimized. The ability of the nanowafer to adherence and dissolution on the cornea has been optimized. The ability of the nanowafer to enable the drug molecules to diffuse into the corneal tissue for up to 2 days has been optimized. Presently studies are underway to evaluate the efficacy of Doxcycline, Dexamethasone, and Cyclosporine-A loaded nanowafers in ocular burn induced mouse model. These studies focus on quantification of the drug-nanowafer efficacy by time to epithelial healing using confocal fluorescence imaging and measurement of expression of relevant inflammatory mediator genes by real-time PCR.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2015
- Accession Number
- ADA626553
Entities
People
- Stephen C. Pflugfelder
Organizations
- Baylor College of Medicine